{"id":"W4410820157","doi":"10.1200/jco.2025.43.16_suppl.tps617","title":"Adjuvant WIDER: A phase 3b trial of ribociclib (RIB) + endocrine therapy (ET) as adjuvant treatment (tx) in a close-to-clinical-practice patient (pt) population with HR+/HER2− early breast cancer (EBC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Adjuvant; Breast cancer; Cancer; Clinical Practice; Population; Oncology; Clinical trial; Internal medicine; Adjuvant therapy; Endocrine system; Gynecology; Surgery; Family medicine; Hormone","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002469799,0.0009965104,0.0009820281,0.0002244671,0.0002571523,0.0008508158,0.0006725742,0.00100813,0.009569802],"category_scores_gemma":[0.001856784,0.0003205246,0.0008588851,0.0002458571,0.0006919457,0.0009877435,0.0007315296,0.002863875,0.00141219],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006234917,"about_ca_system_score_gemma":0.001044799,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004921547,"about_ca_topic_score_gemma":0.002068791,"domain_scores_codex":[0.9994561,0.0003345851,0.00001875195,0.00007789808,0.00003922939,0.00007350399],"domain_scores_gemma":[0.9991291,0.0001511717,0.0002570468,0.00007924547,0.00004784861,0.000335567],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7732004,0.03567535,0.005275144,0.001907709,0.001467624,0.0002130258,0.0002689423,0.002880724,0.01523889,0.001046079,0.01634151,0.1464846],"study_design_scores_gemma":[0.7787685,0.1956921,0.008731875,0.0002105624,0.0007958135,0.0004718491,0.0001297428,0.00124801,0.001227834,0.00101147,0.011673,0.00003936862],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9675204,0.006901406,0.001439582,0.00260842,0.0004993972,0.005867507,0.003890575,0.0002964022,0.01097623],"genre_scores_gemma":[0.9638442,0.004268335,0.004792217,0.005044293,0.0005147568,0.008038334,0.005697097,0.00008514577,0.007715715],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009569802,"threshold_uncertainty_score":0.03201413,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08150653700977262,"score_gpt":0.5433641036047657,"score_spread":0.4618575665949931,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}